Nashai Biotech LLC, a product research, development and procurement company for nutritional supplements, over-the-counter medications and active pharmaceutical ingredients (APIs), announced that its patent-pending process successfully preserves and protects theaflavins as active ingredients from raw material to finished product. Nashai processes meet bulk API and current good manufacturing practices (cGMP).

"Over the past few years, Nashai has developed processes for extracting theaflavins from tea," says Michael Vaughn, president and CEO of Nashai Biotech. "Researchers have found that theaflavins degrade and lose their active properties when they are made into a powder or liquid and are exposed to the natural environment. Nashai's proprietary technology preserves and protects the active ingredient theaflavin, ensuring bioavailability, as well as safety and shelf life for two years."

Theaflavins are unique active ingredients, which are produced when green tea ferments and changes into black or oolong tea. Nashai Biotech developed standard operating procedures for extracting and testing theaflavins that have been validated and duplicated by independent laboratories in the United States and further tested for contaminants.

"Nashai's proprietary nutritional supplement, called Teaflavin, was developed and tested as though it were an active pharmaceutical ingredient," adds Jim Zhao, Chief Science Officer of Nashai Biotech, pointing out that tea scientists recognize the medicinal benefits of theaflavins and have studied their positive effects on cardiovascular health, cancer, immune system, metabolism, diabetes and other areas.

Teaflavin has undergone extensive testing, in both animals and humans, including two years of actual stability, safety and toxicity tests as well as testing for pesticides, herbicides and heavy metals. Proven to be safe and efficacious, Teaflavin originates as organically grown tea, and the finished product is GMO-free and PCR negative.

Teaflavin will be marketed by Nashai through exclusive licensing agreements in multiple distribution channels.